Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2012

01-10-2012

Biomarkers of deep venous thrombosis

Authors: Huacheng Hou, Zhijuan Ge, Pu Ying, Jin Dai, Dongquan Shi, Zhihong Xu, Dongyang Chen, Qing Jiang

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2012

Login to get access

Abstract

Deep venous thrombosis (DVT), which is associated with pulmonary embolism, is a fatal disease because of its high morbidity and mortality in outpatients and inpatients, especially in hospitalized patients. At the same time, lack of subjective clinical symptoms and objective clinical signs makes the diagnosis complicated. Historically, the primarily imaging modalities, including duplex ultrasound, helical CT scans, and venography, establish the diagnosis of DVT. Currently, both imaging modalities and serology are utilized. These plasma molecules are regarded as the biomarkers of DVT including D-dimer, P-selectin, Factor VIII, thrombin generation, inflammatory cytokines, microparticles, fibrin monomer, leukocyte count and so on. This brief review is used to analyze the contribution of the biomarkers to diagnosis and guidance of therapy for DVT.
Literature
1.
Virchow R (1856) Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. A M Von Meidinger Sohn, Frankfurt, p 525–530
2.
3.
McEver RP (2001) Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 86(3):746–756PubMed
4.
Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP (1990) Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 343(6260):757–760PubMedCrossRef
5.
Moore KL, Stults NL, Diaz S, Smith DF, Cummings RD, Varki A, McEver RP (1992) Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol 118(2):445–456PubMedCrossRef
6.
Furie B, Furie BC (2004) Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 10(4):171–178PubMedCrossRef
7.
Sako D, Chang XJ, Barone KM, Vachino G, White HM, Shaw G, Veldman GM, Bean KM, Ahern TJ, Furie B, Cumming DA, Larsen GR (1993) Expression cloning of a functional glycoprotein ligand for P-selectin. Cell 75(6):1179–1186PubMedCrossRef
8.
Théorêt JF, Yacoub D, Hachem A, Gillis MA, Merhi Y (2011) P-selectin ligation induces platelet activation and enhances microaggregate and thrombus formation. Thromb Res 128(3):243–250PubMedCrossRef
9.
Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B (1992) Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359(6398):848–851PubMedCrossRef
10.
Miszti-Blasius K, Debreceni IB, Felszeghy S, Dezso B, Kappelmayer J (2011) Lack of P-selectin glycoprotein ligand-1 protects mice from thrombosis after collagen/epinephrine challenge. Thromb Res 127(3):228–234PubMedCrossRef
11.
Ramacciotti E, Myers DD Jr, Wrobleski SK, Deatrick KB, Londy FJ, Rectenwald JE, Henke PK, Schaub RG, Wakefield TW (2010) P-selectin/PSGL-1 Inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. Thromb Res 125(4):138–142CrossRef
12.
Hrachovinová I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD (2003) Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 9(8):1020–1025PubMedCrossRef
13.
Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y (2000) Transfer of TF from leukocytes to platelets is mediated by CD15 and TF. Blood 96(1):170–175PubMed
14.
Rectenwald JE, Myers DD Jr, Hawley AE, Longo C, Henke PK, Guire KE, Schmaier AH, Wakefield TW (2005) D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost 94(6):1312–1317PubMed
15.
Ramacciotti E, Blackburn S, Hawley AE, Vandy F, Ballard-Lipka N, Stabler C, Baker N, Guire KE, Rectenwald JE, Henke PK, Myers DD Jr, Wakefield TW (2011) Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost 17(4):425–431PubMedCrossRef
16.
Lee DS, Larson MG, Lunetta KL, Dupuis J, Rong J, Keaney JF Jr, Lipinska I, Baldwin CT, Vasan RS, Benjamin EJ (2008) Clinical and genetic correlates of soluble P-selectin in the community. J Thromb Haemost 6(1):20–31PubMedCrossRef
17.
Ay C, Jungbauer LV, Sailer T, Tengler T, Koder S, Kaider A, Panzer S, Quehenberger P, Pabinger I, Mannhalter C (2007) High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 53(7):1235–1243PubMedCrossRef
18.
de Uitte Willige S, De Visser MC, Vos HL, Houwing-Duistermaat JJ, Rosendaal FR, Bertina RM (2008) Selectin haplotypes and the risk of venous thrombosis: influence of linkage disequilibrium with the factor V Leiden mutation. J Thromb Haemost 6(3):478–485CrossRef
19.
Undas A, Tracz W, Siudak Z (2009) Thr715Pro P-selectin polymorphism and P-selectin release in blood obtained from the bleeding time wounds in patients with deep-vein thrombosis. Thromb Res 124(2):248–250PubMedCrossRef
20.
Adam SS, Key NS, Greenberg CS (2009) D-dimer antigen: current concepts and future prospects. Blood 113(13):2878–2887PubMedCrossRef
21.
Khaira HS, Mann J (1998) Plasma D-dimer measurements in patients with suspected DVT—a means of avoiding unnecessary venography. Eur J Vasc Endovasc Surg 15(3):235–238PubMedCrossRef
22.
Castro D, Pérez-Rodríguez E, Montaner L, Flores J, Neuvo GD (2001) Diagnostic value of D dimer in pulmonary embolism and pneumonia. Respiration 68(4):371–375PubMedCrossRef
23.
Perrier A (2004) D-dimer for suspected pulmonary embolism: whom should we test? Chest 125(3):807–809PubMedCrossRef
24.
Mountain D, Jacobs I, Haig A (2007) The VIDAS D-dimer test for venous thromboembolism: a prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice. Am J Emerg Med 25(4):464–471PubMedCrossRef
25.
Ho CH (2011) Can very high level of D-dimer exclusively predict the presence of thromboembolic diseases? J Chin Med Assoc 74(4):151–154PubMedCrossRef
26.
Bozic M, Blinc A, Stegnar M (2002) D-dimer, other markers of haemostasis activation and soluble adhesion molecules in patients with different clinical probabilities of deep vein thrombosis. Thromb Res 108(2–3):107–114PubMedCrossRef
27.
Sohne M, Kruip MJ, Nijkeuter M, Tick L, Kwakkel H, Halkes SJ, Huisman MV, Buller HR (2006) Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost 4(5):1042–1046PubMedCrossRef
28.
Douma RA, le Gal G, Söhne M, Righini M, Kamphuisen PW, Perrier A, Kruip MJ, Bounameaux H, Büller HR, Roy PM (2010) Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ 340:c1475PubMedCrossRef
29.
Anderson DR, Kovacs MJ, Kovacs G, Stiell I, Mitchell M, Khoury V, Dreyer J, Ward J, Wells PS (2003) Combined use of clinical assessment and D-dimer to improve the management of patients presenting to the emergency department with suspected deep vein thrombosis (the EDITED Study). J Thromb Haemost 1(3):645–651PubMedCrossRef
30.
Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ (2003) Evaluation of D-dimer in the diagnosis of suspected deep vein thrombosis. N Engl J Med 349(13):1227–1235PubMedCrossRef
31.
Hirai LK, Takahashi JM, Yoon HC (2007) A prospective evaluation of a quantitative assay in the evaluation of acute pulmonary embolism. J Vasc Interv Radiol 18(8):970–974PubMedCrossRef
32.
Gimber LH, Travis RI, Takahashi JM, Goodman TL, Yoon HC (2009) Computed tomography angiography in patients evaluated for acute pulmonary embolism with low serum D-dimer levels: a prospective study. Perm J 13(4):4–10PubMed
33.
Hurwitz LM, Reiman RE, Yoshizumi TT, Goodman PC, Toncheva G, Nguyen G, Lowry (2007) Radiation dose from contemporary cardiothoracic multidetector CT protocols with an anthropomorphic female phantom: implications for cancer induction. Radiology 245(3):742–750PubMedCrossRef
34.
Lufft V, Hoogestraat-Lufft L, Fels LM, Egbeyong-Baiyee D, Tusch G, Galanski M, Olbricht CJ (2002) Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis 40(2):236–242PubMedCrossRef
35.
Ost D, Khanna D, Shah R, Hall CS, Shah S, Lesser M, Fein AM (2004) Impact of spiral computed tomography on the diagnosis of pulmonary embolism in a community hospital setting. Respiration 71(5):450–457PubMedCrossRef
36.
Crowther MA, Cook DJ, Griffith LE, Meade M, Hanna S, Rabbat C, Bates SM, Geerts W, Johnston M, Guyatt G (2005) Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients. Intensive Care Med 31(1):48–55PubMedCrossRef
37.
Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A (2006) D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 335(17):1780–1789CrossRef
38.
Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, Prisco D, Poli D, Tripodi A, Marongiu F, Palareti G (2010) Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 115(3):481–488PubMedCrossRef
39.
Becattini C, Lignani A, Masotti L, Forte MB, Agnelli G (2012) D-dimer for risk stratification in patients with acute pulmonary embolism. J Thromb Thrombolysis 33(1):48–57PubMedCrossRef
40.
O’Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M (1997) High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 77(5):825–828PubMed
41.
Tanaka KA, Key NS, Levy JH (2009) Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 108(5):1433–1446PubMedCrossRef
42.
Ota S, Yamada N, Ogihara Y, Tsuji A, Ishikura K, Nakamura M, Wada H, Ito M (2011) High plasma level of factor VIII: an important risk factor for venous thromboembolism. Circ J 75(6):1472–1475PubMedCrossRef
43.
Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345(8943):152–155PubMedCrossRef
44.
Kraaijenhagen RA, in’t Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Büller HR (2000) High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83(1):5–9PubMed
45.
Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343(7):457–462PubMedCrossRef
46.
O’Donnell J, Mumford AD, Manning RA, Laffan M (2000) Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase reaction. Thromb Haemost 83(1):10–13PubMed
47.
Tichelaar V, Mulder A, Kluin-Nelemans H, Meijer K (2012) The acute phase reaction explains only a part of initially elevated factor VIII:C levels: a prospective cohort study in patients with venous thrombosis. Thromb Res 129(2):183–186PubMedCrossRef
48.
Soria JM, Almasy L, Souto JC, Buil A, Martinez-Sanchez E, Mateo J, Borrell M, Stone WH, Lathrop M, Fontcuberta J, Blangero J (2003) A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 101(1):163–167PubMedCrossRef
49.
Viel KR, Machiah DK, Warren DM, Khachidze M, Buil A, Fernstrom K, Souto JC, Peralta JM, Smith T, Blangero J, Porter S, Warren ST, Fontcuberta J, Soria JM, Flanders WD, Almasy L, Howard TE (2007) A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 109(9):3713–3724PubMedCrossRef
50.
Singh I, Smith A, Vanzieleghem B, Collen D, Burnand K, Saint-Remy JM, Jacquemin M (2002) Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood 99(9):3235–3240PubMedCrossRef
51.
Emmerechts J, Vanassche T, Loyen S, Van Linthout I, Cludts K, Kauskot A, Long C, Jacquemin M, Hoylaerts MF, Verhamme P (2011) Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis. Thromb Res. doi:10.​1016/​j.​thromres.​2011.​06.​027
52.
Macfarlane RG, Biggs R (1953) A thrombin generation test: the application in haemophilia and thrombocytopenia. J Clin Pathol 6(1):3–8PubMedCrossRef
53.
Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33(1):4–15PubMedCrossRef
54.
Van Veen JJ, Gatt A, Makris M (2008) Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 142(6):889–903PubMedCrossRef
55.
Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR (2005) Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 3(11):2497–2505PubMedCrossRef
56.
Dargaud Y, Béguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C (2005) Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 93(3):475–480PubMed
57.
58.
Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA (2006) Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296(4):397–402PubMedCrossRef
59.
Lutsey PL, Folsom AR, Heckbert SR, Cushman M (2009) Peak thrombin generation and subsequent venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE) study. J Thromb Haemost 7(10):1639–1648PubMedCrossRef
60.
van Hylckama VliegA, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP (2007) Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 138(6):769–774CrossRef
61.
Segers O, van Oerle R, ten Cate H, Rosing J, Castoldi E (2010) Thrombin generation as an intermediate phenotype for venous thrombosis. Thromb Haemost 103(1):114–122PubMedCrossRef
62.
Haas FJ, Schutgens RE, Kluft C, Biesma DH (2011) A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly. Scand J Clin Lab Invest 71(1):12–18PubMedCrossRef
63.
Osnes LT, Westvik AB, Joø GB, Okkenhaug C, Kierulf P (1996) Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13. Cytokine 8(11):822–827PubMedCrossRef
64.
Folsom AR, Lutsey PL, Astor BC, Cushman M (2009) C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 102(4):615–619PubMed
65.
Zacho J, Tybjaerg-Hansen A, Nordestgaard BG (2010) C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 30(8):1672–1678PubMedCrossRef
66.
Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR (2002) Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113(8):636–642PubMedCrossRef
67.
Thomas EA, Cobby MJ, Rhys Davies E, Jeans WD, Whicher JT (1989) Liquid crystal thermography and C reactive protein in the detection of deep venous thrombosis. BMJ 299(6705):951–952PubMedCrossRef
68.
Wong NA, Laitt RD, Goddard PR, Virjee J (1996) Serum C reactive protein does not reliably exclude lower limb deep venous thrombosis. Thromb Haemost 76(5):816–817PubMed
69.
Maskell NA, Butland RJ (2001) A normal serum CRP measurement does not exclude deep vein thrombosis. Thromb Haemos 86(6):1582–1583
70.
Bucek RA, Reiter M, Quehenberger P, Minar E (2002) C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol 119(2):385–389PubMedCrossRef
71.
Fox EA, Kahn SR (2005) The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 94(2):362–365PubMed
72.
Reitsma PH, Rosendaal FR (2004) Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2(4):619–622PubMedCrossRef
73.
Poredos P, Jezovnik MK (2011) In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels 26(6):596–602PubMedCrossRef
74.
Vormittag R, Hsieh K, Kaider A, Minar E, Bialonczyk C, Hirschl M, Mannhalter C, Pabinger I (2006) Interleukin-6 and interleukin-6 promoter polymorphism (-174) G > C in patients with spontaneous venous thromboembolism. Thromb Haemost 95(5):802–806PubMed
75.
Christiansen SC, Naess IA, Cannegieter SC, Hammerstrøm J, Rosendaal FR, Reitsma PH (2006) Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med 3(8):e334PubMedCrossRef
76.
Beckers MM, Ruven HJ, Haas FJ, Doevendans PA, ten Cate H, Prins MH, Biesma DH (2010) Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. Eur J Intern Med 21(4):289–292PubMedCrossRef
77.
Zee RY, Glynn RJ, Cheng S, Steiner L, Rose L, Ridker PM (2009) An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: the Women’s Genome Health Study. Circ Cardiovasc Genet 2(1):57–62PubMedCrossRef
78.
Matos MF, Lourenço DM, Orikaza CM, Bajerl JA, Noguti MA, Morelli VM (2011) The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6-174GC, IL-8-251AT and MCP-1-2518AG in the risk of venous thromboembolism: a case-control study. Thromb Res 128(3):216–220PubMedCrossRef
79.
Downing LJ, Strieter RM, Kadell AM, Wilke CA, Austin JC, Hare BD, Burdick MD, Greenfield LJ, Wakefield TW (1998) IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. J Immunol 161(3):1471–1476PubMed
80.
Rectenwald JE, Myers DD Jr, Hawley AE, Longo C, Henke PK, Guire KE, Schmaier AH, Wakefield TW (2005) D-Dimer, P-Selectin, and microparticles: novel markers to predict deep venous thrombosis. Thromb Haemost 94(6):1312–1317PubMed
81.
Key NS, Chantrathammachart P, Moody PW, Chang JY (2010) Membrane microparticles in VTE and cancer. Thromb Res 125:80–83CrossRef
82.
Ahn YS (2005) Cell-drived microparticles: “Miniature envoys with many faces”. J Thromb Haemost 3(5):884–887PubMedCrossRef
83.
VanWijk MJ, VanBavel E, Sturk A, Nieuwland R (2003) Microparticles in cardiovascular diseases. Cardiovasc Res 59:277–287PubMedCrossRef
84.
Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S, Simioni P (2011) Endothelial, platelet, and TF-bearing microparticles in canner patients with and without thromboembolism. Thromb Res 127(5):473–477PubMedCrossRef
85.
Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, Freyssinet JM (2006) Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 26(12):2594–2604PubMedCrossRef
86.
Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, Horstman LL, Soriano AO, Zambrano JP, Ahn YS (2005) Elevation of endothelial microparticles, platelets, and leucocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 45(9):1467–1471PubMedCrossRef
87.
Ghosh A, Li W, Febbraio M, Espinola RG, McCrae KR, Cockrell E, Silverstein RL (2008) Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 118(5):1934–1943PubMed
88.
Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD (2003) Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 9(8):1020–1025PubMedCrossRef
89.
Ramacciotti E, Hawley AE, Farris DM, Ballard NE, Wrobleski SK, Myers DD Jr, Henke PK, Wakefield TW (2009) Leukocyte- and platelet-derived microparticles correlate with thrombus weight and TF activity in an experimental mouse model of venous thrombosis. Thromb Haemost 101(4):748–754PubMed
90.
Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G (2007) Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110(7):2440–2448PubMedCrossRef
91.
Reich CF III, Pisetsky DS (2009) The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis. Exp Cell Res 315(5):760–768PubMedCrossRef
92.
Fuster V (1994) Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90(4):2126–2146PubMedCrossRef
93.
Vogel G, Dempfle CE, Spannagel M, Leskopf W (1996) The value of quantitative fibrin monomer determination in the early diagnosis of postoperative deep vein thrombosis. Thromb Res 81(2):241–251PubMedCrossRef
94.
Reber G, Blanchard J, Bounameaux H, Hoffmeyer P, Miron MJ, Leyvraz PF, de Moerloose P (2000) Inability of serial fibrin monomer measurements to predict or exclude deep venous thrombosis in asymptomatic patients undergoing total knee arthroplasty. Blood Coagul Fibrinolysis 11(3):305–308PubMed
95.
Wada H, Sakuragawa N (2008) Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost 34(1):33–38PubMedCrossRef
96.
Dopsaj V, Bogavac-Stanojevic N, Vasic D, Vukosavljevic D, Martinovic J, Kotur-Stevuljevic J, Spasic S (2009) Excluding deep venous thrombosis in symptomatic outpatients: is fibrin monomer aid to D-dimer analysis? Blood Coagul Fibrinolysis 20(7):546–551PubMedCrossRef
97.
Park KJ, Kwon EH, Kim HJ, Kim SH (2011) Evaluation of the diagnostic performance of fibrin monomer in disseminated intravascular coagulation. Korean J Lab Med 31(3):143–147PubMedCrossRef
98.
Semeraro N, Biondi A, Lorenzet R, Locati D, Mantovani A, Donati MB (1983) Direct induction of TF synthesis by endotoxin in human macrophages from diverse anatomical sites. Immunology 50(4):529–535PubMed
99.
Schaub RG, Simmons CA, Koets MH, Romano PJ 2nd, Stewart GJ (1984) Early events in the formation of a venous thrombus following local trauma and stasis. Lab Invest 51(2):218–224PubMed
100.
Stoffel N, Rysler C, Buser A, Gratwohl A, Tsakiris DA, Stern M (2010) Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy. Thromb Haemost 103(6):1228–1232PubMedCrossRef
101.
Tefferi A, Gangat N, Wolanskyj A (2007) The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 109(9):4105PubMedCrossRef
102.
Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, Boggi S, Astori C, Bernasconi P, Varettoni M, Brusamolino E, Pascutto C, Lazzarino M (2008) Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 93(11):1645–1651PubMedCrossRef
103.
Passamonti F, Rumi E, Pascutto C, Cazzola M, Lazzarino M (2009) Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 7(9):1587–1589PubMedCrossRef
104.
Hoch RC, Schraufstätter IU, Cochrane CG (1996) In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors. J Lab Clin Med 128(2):134–145PubMedCrossRef
105.
Luster AD (1998) Chemokines–chemotactic cytokines that mediate inflammation. N Engl J Med 338(7):436–445PubMedCrossRef
106.
Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM (1995) Prevalence of protein C deficiency in the healthy population. Throm Haemost 73(1):87–93
107.
Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW (1994) Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 87(1):106–112PubMedCrossRef
108.
McColl M, Tait RC, Walker ID, Perry DJ, McCall F, Conkie JA (1996) Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 7(7):689–694PubMedCrossRef
109.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67PubMedCrossRef
110.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698–3703PubMed
111.
Morelli VM, De Visser MC, Vos HL, Bertina RM, Rosendaal FR (2005) ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 3(1):183–185PubMedCrossRef
112.
den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334(12):759–762CrossRef
113.
Kyrle PA, Eichinger S (2005) Deep vein thrombosis. Lancet 365(9465):116–174CrossRef
114.
Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B (1997) Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 350(9094):1795–1798PubMedCrossRef
Metadata
Title
Biomarkers of deep venous thrombosis
Authors
Huacheng Hou
Zhijuan Ge
Pu Ying
Jin Dai
Dongquan Shi
Zhihong Xu
Dongyang Chen
Qing Jiang
Publication date
01-10-2012
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2012
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-012-0721-y

Other articles of this Issue 3/2012

Journal of Thrombosis and Thrombolysis 3/2012 Go to the issue

OriginalPaper

Effects on platelet function of a direct acting antagonist of coagulation factor Xa

OriginalPaper

Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction

OriginalPaper

Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis

Letter to the Editor

Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura

OriginalPaper

Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

OriginalPaper

Economic evaluation of the use of point-of-care devices in patients with long term oral anticoagulation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits